High-dose transdermal nicotine replacement for tobacco cessation

Area of Science:

• Pharmacology
• Addiction Medicine
• Public Health

Background:

• Nicotine-replacement therapy (NRT) is a cornerstone of tobacco cessation.
• Standard transdermal nicotine doses (7-21 mg/day) are FDA-approved but may be insufficient for heavy smokers.
• The potential role of higher-dose NRT (≥42 mg/day) requires further investigation.

Purpose of the Study:

• To review the safety and efficacy of high-dose transdermal nicotine-replacement therapy (NRT) for tobacco-use cessation.
• To synthesize findings from existing literature on NRT doses of ≥42 mg daily.

Main Methods:

• A literature search was conducted to identify English-language studies evaluating transdermal nicotine doses of ≥42 mg daily.
• Eleven articles representing 10 trials were identified and analyzed.

Main Results:

• Most trials reported no serious adverse events with high-dose transdermal NRT (≥42 mg/day).
• A dose-response relationship was observed for adverse events in most trials.
• While numerically higher abstinence rates were noted with high-dose NRT, no statistically significant differences in final abstinence rates were found.
• Limitations such as small sample sizes and lack of power calculations may have impacted statistical significance.

Conclusions:

• The safety and efficacy of high-dose transdermal NRT for tobacco cessation are not definitively established in the current medical literature.
• Further robust clinical trials are necessary to confirm the benefits of higher nicotine transdermal doses.
• Identifying specific patient populations who would benefit most from high-dose NRT requires additional research.